KR20110005783A - 질환 마커 및 그의 용도 - Google Patents

질환 마커 및 그의 용도 Download PDF

Info

Publication number
KR20110005783A
KR20110005783A KR1020107019933A KR20107019933A KR20110005783A KR 20110005783 A KR20110005783 A KR 20110005783A KR 1020107019933 A KR1020107019933 A KR 1020107019933A KR 20107019933 A KR20107019933 A KR 20107019933A KR 20110005783 A KR20110005783 A KR 20110005783A
Authority
KR
South Korea
Prior art keywords
expression
activity
oasl
profile
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107019933A
Other languages
English (en)
Korean (ko)
Inventor
위홍 야오
크리스 모어하우스
브랜던 힉스
바히자 자랄
스티븐 에이 그린버그
Original Assignee
메디뮨 엘엘씨
브리검앤드위민즈하스피탈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨, 브리검앤드위민즈하스피탈, 인코포레이티드 filed Critical 메디뮨 엘엘씨
Publication of KR20110005783A publication Critical patent/KR20110005783A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107019933A 2008-02-08 2009-02-06 질환 마커 및 그의 용도 Ceased KR20110005783A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US696308P 2008-02-08 2008-02-08
US61/006,963 2008-02-08

Publications (1)

Publication Number Publication Date
KR20110005783A true KR20110005783A (ko) 2011-01-19

Family

ID=40952717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107019933A Ceased KR20110005783A (ko) 2008-02-08 2009-02-06 질환 마커 및 그의 용도

Country Status (12)

Country Link
US (1) US20110262928A1 (enExample)
EP (2) EP2848702A1 (enExample)
JP (1) JP2011511804A (enExample)
KR (1) KR20110005783A (enExample)
CN (1) CN101999001B (enExample)
AU (1) AU2009212216B2 (enExample)
BR (1) BRPI0908065A2 (enExample)
CA (1) CA2714410A1 (enExample)
ES (1) ES2529593T3 (enExample)
MX (1) MX2010008698A (enExample)
SG (1) SG188147A1 (enExample)
WO (1) WO2009100342A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2692784C (en) * 2007-07-12 2018-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for diagnosing and assessing inflammatory myopathies
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US8785414B2 (en) * 2009-03-31 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome
SMT201700063T1 (it) * 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
JPWO2011126105A1 (ja) * 2010-04-08 2013-07-11 啓之 吉富 免疫系の異常疾患または関節系の異常疾患への罹患またはこれらの病勢を判定するための検査方法
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2013020926A1 (en) * 2011-08-11 2013-02-14 Febit Holding Gmbh Complex sets of mirnas as non-invasive biomarkers for psoriasis
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP2653554A1 (en) * 2012-04-17 2013-10-23 Istituto Nazionale Di Genetica Molecolare-INGM Immune response biomarkers
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
EP3013985A4 (en) * 2013-06-28 2017-07-19 Acumen Research Laboratories Pte. Ltd. Sepsis biomarkers and uses thereof
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
JP6531306B2 (ja) * 2015-02-20 2019-06-19 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
WO2019210179A1 (en) * 2018-04-27 2019-10-31 Stemline Therapeutics, Inc. Methods of treating an autoimmune disease with a human interleukin-3 (il-3)-diphtheria toxin conjugate (dt-il3)
CN110085282A (zh) * 2019-04-23 2019-08-02 华中师范大学 核酸结构中核苷酸与核苷酸相互作用预测的方法
CN110108880A (zh) * 2019-05-30 2019-08-09 四川大学华西医院 Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110161235B (zh) * 2019-06-26 2022-04-12 江苏省中医院 三种血清蛋白联合用于强直性脊柱炎诊断的用途
KR20220084305A (ko) * 2019-10-04 2022-06-21 더 리젠츠 오브 더 유니버시티 오브 미시간 건선의 치료에서 항-종양 괴사 인자 치료법에 대한 반응성을 결정하는 방법
CN111378742A (zh) * 2020-04-16 2020-07-07 嘉兴程瑞医药科技有限公司 microRNA生物标志物及其在制备自身免疫疾病检测试剂盒中的应用
CN113388677A (zh) * 2021-06-17 2021-09-14 河北医科大学第二医院 包括ifi44的干燥症诊断标志物组合
CN117554614A (zh) * 2022-09-23 2024-02-13 上海市第十人民医院 蛋白生物标志物dpp4在克罗恩病临床诊断中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US7833795B2 (en) * 2004-08-24 2010-11-16 The Trustees Of The University Of Pennsylvania Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
ES2432026T3 (es) * 2005-08-05 2013-11-29 Genentech, Inc. Métodos y composiciones para detectar trastornos autoinmunes
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
WO2009100342A2 (en) 2009-08-13
US20110262928A1 (en) 2011-10-27
CN101999001A (zh) 2011-03-30
EP2252703A4 (en) 2011-12-21
EP2252703B1 (en) 2014-11-05
JP2011511804A (ja) 2011-04-14
AU2009212216A1 (en) 2009-08-13
BRPI0908065A2 (pt) 2015-08-11
CN101999001B (zh) 2013-11-20
WO2009100342A3 (en) 2009-12-30
HK1150063A1 (en) 2011-10-28
EP2252703A2 (en) 2010-11-24
MX2010008698A (es) 2010-12-20
AU2009212216B2 (en) 2015-04-09
SG188147A1 (en) 2013-03-28
ES2529593T3 (es) 2015-02-23
EP2848702A1 (en) 2015-03-18
CA2714410A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
CN101999001B (zh) 疾病标志物及其用途
AU2007327995B2 (en) Interferon alpha-induced pharmacodynamic markers
AU2008247398B2 (en) Interferon alpha-induced pharmacodynamic markers
AU2010289383B2 (en) Type 1 interferon diagnostic
US20110287022A1 (en) Interferon alpha-induced pharmacodynamic markers
WO2010060999A1 (en) Predicting clinical response to treatment with a soluble tnf-antagonist, or tnf, or a tnf receptor agonist
US20100261172A1 (en) Interferon alpha-induced pharmacodynamic markers
WO2009155559A1 (en) Interferon alpha-induced pharmacodynamic markers
AU2015203772A1 (en) Disease markers and uses thereof
HK1150063B (en) Disease markers and uses thereof
AU2014200127A1 (en) Interferon alpha-induced pharmacodynamic markers
AU2014200128A1 (en) Interferon alpha-induced pharmacodynamic markers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100907

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140206

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150701

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151016

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150701

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I